Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection- Interventions from Small Businesses (U44 Clinical Trial Not Allowed) | RFA NS 22 067

Frequently Asked Questions (FAQs)

What is the Stroke Preclinical Assessment Network (SPAN) funding opportunity?

SPAN (RFA-NS-22-067) is an NIH National Institute of Neurological Disorders and Stroke (NINDS) initiative that supports small businesses in advancing promising stroke therapies through a rigorous, network-based preclinical testing pathway. The program is designed to generate standardized, decision-quality preclinical evidence to help identify which candidates are most likely to succeed in later, pivotal clinical trials.

What type of projects does this announcement support?

This funding opportunity specifically supports Phase II SBIR projects focused on preclinical evaluation of acute cerebroprotective interventions for ischemic stroke. The work is centered on experimental stroke models and is intended for interventions that already have strong preliminary evidence.

What is the funding mechanism used for SPAN awards?

SPAN uses a U44 cooperative agreement mechanism. As a cooperative agreement, it is structured for substantial NIH programmatic involvement and is designed to support coordinated, network-based work rather than isolated, single-lab efforts.

Are clinical trials allowed under this funding opportunity?

No. Clinical trials are not allowed under this announcement. The program is focused on preclinical testing in experimental stroke models.

What disease area and therapeutic focus does SPAN prioritize?

SPAN is focused on acute cerebroprotection for ischemic stroke. It prioritizes therapies intended to reduce brain injury around the time blood flow is restored (reperfusion), with the goal of improving outcomes beyond what reperfusion alone can achieve.

When should the intervention be administered according to the program’s scientific focus?

The program targets cerebroprotective drugs or other interventions that would be administered prior to reperfusion or right around the time reperfusion occurs. This aligns with modern stroke care where reperfusion (for example, via thrombectomy or thrombolysis) is common, but reperfusion can also drive secondary injury processes.

What kinds of interventions are appropriate for SPAN?

Appropriate interventions include cerebroprotective drugs or other cerebroprotective strategies aimed at limiting brain damage during the acute ischemia-to-reperfusion window. The intervention is expected to be sufficiently mature and supported by rigorous, extensive preliminary data.

Is SPAN intended for early-stage discovery or speculative concepts?

No. SPAN is not positioned as an early discovery program. It is intended for interventions that already look highly promising based on strong preliminary evidence and are ready for a structured, higher-confidence preclinical assessment as the next step toward human trials.

What is the main goal of using a network-based preclinical testing pathway?

The main goal is to evaluate candidates in a standardized, collaborative framework that is meant to better predict which therapies are most likely to translate successfully into later-stage development and pivotal clinical trials. The network approach emphasizes consistency and transparency in study design, execution, analysis, and reporting.

How does SPAN address common translation problems in stroke therapeutics?

The program is designed to address the long-standing challenge that many stroke therapy candidates appear promising in early studies but fail to translate when moved toward clinical testing. SPAN aims to reduce these failures by using harmonized, multi-site studies and standardized methods, generating more robust and comparable preclinical evidence.

Will applicants conduct studies independently, or as part of a larger consortium?

Funded principal investigators effectively join the SPAN consortium and are expected to collaborate closely with the SPAN Coordinating Center, designated preclinical testing laboratories supported through companion funding, and other intervention contributors funded through related FOAs.

What SPAN components will awardees be expected to coordinate with?

Awardees are expected to work with multiple coordinated components, including the SPAN Coordinating Center and designated preclinical testing laboratories, as well as other intervention contributors within the broader SPAN effort supported through related announcements.

What preclinical models are anticipated for use in SPAN testing?

The network anticipates using established ischemic stroke models such as transient middle cerebral artery occlusion (tMCAo). This model is widely used to mimic key features of human ischemic stroke and reperfusion injury.

How many interventions does SPAN anticipate testing?

The network anticipates testing up to about eight interventions in parallel.

Why does the FOA emphasize standardized and harmonized studies across multiple sites?

Standardization and harmonization are central to producing comparable, transparent results and enabling side-by-side evaluation across candidates. This approach is intended to generate decision-quality data more efficiently than traditional one-off preclinical projects.

What level of preliminary data is expected to be competitive?

Applicants are expected to bring a cerebroprotective intervention supported by rigorous and extensive preliminary data. The program is aimed at interventions that already appear highly promising and are mature enough for a network-based, rigorous preclinical assessment.

What happens if an intervention performs well within SPAN?

If an intervention performs well, the intended outcome is to de-risk and accelerate its progression into later-stage development and eventual clinical evaluation, creating a clearer pipeline from small-business innovation to clinically actionable stroke therapies.

Who is eligible to apply for this opportunity?

Eligibility is limited to small businesses, consistent with the SBIR program.

Are foreign institutions eligible to apply?

No. Foreign institutions are not eligible to apply under this FOA.

Are non-U.S. components of U.S. organizations eligible to apply?

No. Non-U.S. components of U.S. organizations are also not eligible to apply under this FOA.

Are any foreign activities allowed at all under this opportunity?

Foreign components (as defined in the NIH Grants Policy Statement) may be allowed. This typically means discrete elements of the work could potentially be performed outside the U.S. if they meet NIH policy requirements and are well-justified, even though the applicant organization itself must be U.S.-based and eligible.

Which NIH Institute is associated with this initiative?

This initiative is associated with NIH’s National Institute of Neurological Disorders and Stroke (NINDS).

What is the CFDA number associated with this opportunity?

The opportunity is listed within NIH’s health research portfolio under CFDA 93.853.

What was the original closing date listed for this funding opportunity?

The original closing date listed was July 28, 2022.

What is the award ceiling mentioned in the summary information?

An award ceiling of $300,000 is provided in the summary information.

Why is SPAN described as a cost- and time-effective approach?

The announcement frames SPAN as cost- and time-effective because the network infrastructure reduces duplication of effort and promotes standardized methods, rather than requiring each developer to build an independent preclinical testing ecosystem.

What is the overall purpose of SPAN in the development pipeline?

SPAN is best understood as a translational bridge that connects small business-developed cerebroprotective candidates with disciplined, multi-site preclinical evaluation. The goal is to produce robust evidence that helps determine which interventions truly warrant the cost and risk of future pivotal clinical trials in acute ischemic stroke.